A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes (T2D) and weight management, yet their broad health impacts in real-world settings remain understudied. Using data from the All of Us Research Progr…
With the rising prevalence of T2D worldwide, peripheral artery disease (PAD) now affects >230 million individuals globally. In the recent STRIDE trial, Bonaca et al.demonstrated that semaglutide improved walking capacity and hemodynamic parameters an…
Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and also antiobesity treatment. Commercially available therapeutic lipidated GLP-1 analogues, semaglutide an…
Tumor cells have substantially increased lipid biogenesis, which is primarily regulated by the activation of sterol regulatory element-binding protein (SREBP). However, whether SREBP regulation can be targeted for cancer treatment remains unclear. He…
GOALS: Our aim was to perform a national survey of provider attitudes, practices, and knowledge regarding weight loss and MASLD medications in patients with MASLD. BACKGROUND: While weight loss is a cornerstone in the management of metabolic dysfunct…
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text].
INTRODUCTION: To evaluate the impact of prolonged GLP-1 usage on mortality, readmission, incidence of in-hospital complications, and incidence of implant failure following hip fracture surgery across various BMI strata. METHODS: A prospective hip fra…
BACKGROUND: Novel glucagon-like peptide-1 receptor agonists (GLP1RAs) for obesity treatment have generated considerable dialogue on digital media platforms. However, nonevidence-based information from online sources may perpetuate misconceptions abou…
OBJECTIVES: To evaluate semaglutide's multisystem therapeutic benefits across 12 health domains. Primary outcomes were major adverse cardiovascular events, resolution of metabolic dysfunction-associated steatohepatitis, and composite renal endpoints.…
OBJECTIVES: Semaglutide is a glucagon-like peptide 1 (GLP-1) analog that binds to GLP-1 receptors (GLP-1R) on beta-cells and neuronal cells and is used for treating type 2 diabetes and obesity. Insulin-secreting pancreatic neuroendocrine neoplasms ha…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat diabetes and obesity. Emerging evidence suggests that GLP-1 RAs may be linked to increased gastric residual content (GRC), aspiration pneumonia, and aborted…
BACKGROUND: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that shows significant efficacy in treating obesity. However, its associated side effects, including poor patient compliance and gastrointestinal inflammation, are concerni…
The successful treatment of type 2 diabetes and obesity with tirzepatide highlights the dual agonists of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic peptide receptor (GIPR) as a powerful new generation of anti-diabe…
BACKGROUND: The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in patients with weight regain after bariatric surgery remains unclear. The objective of this study was to determine the efficacy and safety of 12 months of GLP1-RA treatmen…